20746-64-9

Basic information

• Product Name: Allyl 4,6-O-benzylidene-alpha-D-glucopyranoside
• Synonyms: Allyl 4,6-O-benzylidene-alpha-D-glucopyranoside;Allyl 4,6-O-benzylidene-a-D-galactopyranoside;Allyl4,6-O-benzylidene-a-D-glucopyranoside;Allyl-4,6-O-benzylidene-α-D-glucopyranoside;Allyl 4,6-O-benzylidene-α-D-galactopyranoside;2-Propenyl 4,6-O-(phenylmethylene)-alpha-D-galactopyranoside;a-D-Galactopyranoside,2-propenyl 4,6-O-(phenylmethylene)- (9CI)
• CAS NO: 20746-64-9
• Molecular Formula: C₁₆H₂₀O₆
• Molecular Weight: 308.3264
• EINECS: 1533716-785-6
• Mol File: 20746-64-9.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Allyl 4,6-O-benzylidene-alpha-D-glucopyranoside(CAS DataBase Reference)
• NIST Chemistry Reference: Allyl 4,6-O-benzylidene-alpha-D-glucopyranoside(20746-64-9)
• EPA Substance Registry System: Allyl 4,6-O-benzylidene-alpha-D-glucopyranoside(20746-64-9)

Safety Data

• Hazardous Substances Data: 20746-64-9(Hazardous Substances Data)

Usage

General Description

Allyl 4,6-O-benzylidene-alpha-D-glucopyranoside is a chemical compound with the molecular formula C17H20O6. It is a derivative of glucose and belongs to the class of glycosides. Allyl 4,6-O-benzylidene-alpha-D-glucopyranoside is commonly used in organic synthesis and as a reagent in chemical reactions. It is also known for its potential use in the development of pharmaceuticals and other bioactive compounds. Allyl 4,6-O-benzylidene-alpha-D-glucopyranoside has been studied for its various biological activities, including antiviral, anticancer, and anti-inflammatory properties, making it a potentially valuable compound for medicinal and pharmaceutical applications.

Upstream product

• 1125-88-8 benzaldehyde dimethyl acetal 
• 48149-72-0 (2S,3R,4S,5R,6R)-2-Allyloxy-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol 
• 25878-60-8 D-galactose pentaacetate 
• 2595-07-5 allyl β-D-glucopyranoside 
• 2280-44-6 D-Glucose 
• 492-61-5 β-D-glucose 
• 10343-15-4 Acetic acid (2R,3R,4S,5R,6R)-3,5-diacetoxy-2-acetoxymethyl-6-allyloxy-tetrahydro-pyran-4-yl ester 
• 604-69-3 β-D-glucose pentaacetate 
• 48149-74-2 allyl D-glucopyranoside 
• 10343-15-4 allyl 2,3,4,6-tetra-O-acetyl-D-galactopyranoside 
• 3006-41-5 4,6-O-benzylidene-α,β-D-galactopyranose 
• 106-95-6 allyl bromide 
• 100-52-7 benzaldehyde 
• 2595-07-5 allyl D-galactopyranoside 

Downstream Products

• 81713-13-5 allyl 4,6-O-benzylidene-2,3-di-O-(2-butenyl)-α-D-galactopyranoside 
• 540474-09-7 allyl 2-O-benzoyl-4,6-O-benzylidene-β-D-glucopyranoside 
• 81713-16-8 1-propenyl 4,6-di-O-benzyl-α-D-galactopyranoside 
• 81713-23-7 2-O-benzoyl-4,6-di-O-benzyl-3-O-tert-butyldimethylsilyl-α,β-D-galactopyranose 
• 81726-71-8 2-O-benzoyl-4,6-di-O-benzyl-3-O-tert-butyldimethylsilyl-α-D-galactopyranosyl chloride 
• 81713-19-1 1-propenyl 2-O-benzoyl-4,6-di-O-benzyl-α-D-galactopyranoside 
• 81726-72-9 2-O-benzoyl-4,6-di-O-benzyl-3-O-(tetrahydro-2-pyranyl)-α-D-galactopyranosyl chloride 
• 81713-24-8 2-O-benzoyl-4,6-di-O-benzyl-3-O-(tetrahydro-2-pyranyl)-α,β-D-galactopyranose 
• 81713-25-9 2,3-di-O-benzoyl-4,6-di-O-benzyl-α-D-galactopyranosyl chloride 
• 81713-21-5 2,3-di-O-benzoyl-4,6-di-O-benzyl-α,β-D-galactopyranose 
• 81713-29-3 2,3-di-O-benzoyl-4,6-di-O-benzyl-α-D-galactopyranosyl bromide 
• 81726-70-7 1-propenyl 2-O-benzoyl-4,6-di-O-benzyl-3-O-tert-butyldimethylsilyl-α-D-galactopyranoside 
• 81713-20-4 1-propenyl 2-O-benzoyl-4,6-di-O-benzyl-3-O-(tetrahydro-2-pyranyl)-α-D-galactopyranoside 
• 81713-17-9 1-propenyl 2,3-di-O-benzoyl-4,6-di-O-benzyl-α-D-galactopyranoside 

Relevant articles and documents

A Synthetic Carbohydrate-Protein Conjugate Vaccine Candidate against Klebsiella pneumoniae Serotype K2

Klebsiella pneumoniae causes pneumonia and liver abscesses in humans worldwide and contains virulence factor capsular polysaccharides and lipopolysaccharides linked to the cell wall. Although capsular polysaccharides are good antigens for vaccine producti

5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors

(2S,3R,4R,5S,6R)-2-Aryl-5,5-difluoro-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diols and (2S,3R,4R,5S,6R)-2-aryl-5-fluoro-5-methyl-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diols were discovered as dual inhibitors of sodium glucose co-transporter proteins (

BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS

The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.